Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:

NCT ID: NCT00524524 Completed - Clinical trials for Advanced Solid Tumors

An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors

Start date: August 2007
Phase: Phase 1
Study type: Interventional

This study is designed to evaluate the response of several biomarkers in patients treated with ARQ 501. The results of the study may help the sponsor understand the effect of the study drug on these biomarkers and their respective role in cancer growth control.

NCT ID: NCT00522652 Completed - Lymphoma Clinical Trials

Phase I Trial of PX-478

Start date: August 2007
Phase: Phase 1
Study type: Interventional

This study is being conducted to determine the safety and biologic activity of PX-478, and to allow for observation of any preliminary evidence of antitumor activity in patients with advanced metastatic cancer.

NCT ID: NCT00520637 Completed - Lymphoma Clinical Trials

A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01)

Start date: May 2007
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to find the highest tolerable dose of EZN-2208 that can be given to patients with advanced cancer or lymphoma. The safety of the study drug and its effect on the disease will also be studied. Enzon will also perform pharmacokinetic (PK) testing of EZN-2208. PK testing measures the amount of a drug in the body at different time points.

NCT ID: NCT00520390 Completed - Lymphoma Clinical Trials

A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02)

Start date: May 2007
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to find the highest tolerable dose of EZN-2208 that can be given to patients with advanced cancer or lymphoma. The safety of the study drug and its effect on the disease will also be studied. Enzon will also perform pharmacokinetic (PK) testing of EZN-2208. PK testing measures the amount of a drug in the body at different time points.

NCT ID: NCT00519662 Completed - Clinical trials for Advanced Solid Tumors

Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors

Start date: August 2007
Phase: Phase 1
Study type: Interventional

This is a study to assess the safety and tolerability of SNS-314 in advanced solid tumors in humans.

NCT ID: NCT00514306 Completed - Clinical trials for Advanced Solid Tumors

Study of Intermittent OSI-906 Dosing

Start date: July 5, 2007
Phase: Phase 1
Study type: Interventional

Multicenter, open-label, phase 1, cohort dose escalation study to determine the maximum tolerated dose (MTD) of 3 intermittent OSI-906 dosing schedules.

NCT ID: NCT00514007 Completed - Clinical trials for Advanced Solid Tumors

Study of Continuous OSI-906 Dosing

Start date: June 18, 2007
Phase: Phase 1
Study type: Interventional

Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) on both Once Daily (QD) and Twice Daily (BID) schedules.

NCT ID: NCT00513851 Completed - Clinical trials for Advanced Solid Tumors

Phase 1 Study of OSI-930 in Cancer Patients

Start date: April 2006
Phase: Phase 1
Study type: Interventional

Open label, phase 1, dose escalation

NCT ID: NCT00507585 Completed - Clinical trials for Advanced Solid Tumors

Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, Leucovorin, and Avastin

Start date: June 2006
Phase: Phase 1
Study type: Interventional

PRIMARY: - To determine the toxicity and tolerability of intra-arterial hepatic oxaliplatin every three weeks administered in combination with systemic intravenous Fluorouracil, Leucovorin and bevacizumab to patients with advanced solid tumors metastatic to the liver. SECONDARY: - To document in a descriptive fashion the antitumor efficacy of this combination regimen. - To evaluate the feasibility and accuracy of an alternate radiographic assessment tool and compare with available tumor markers and RECIST guidelines. - To estimate in a descriptive fashion the development of extrahepatic tumor recurrences.

NCT ID: NCT00487058 Completed - Clinical trials for Advanced Solid Tumors

A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors

Start date: May 2007
Phase: Phase 1
Study type: Interventional

This study assesses the tolerability, safety, efficacy and pharmacokinetics of gimatecan in Japanese patients. Gimatecan is administered orally twice per week, every 28 days, to adult patients with advanced solid tumors who have progressed despite standard therapy or for whom standard systemic therapy dose not exist.